We are live on ! Find out more
SAM

Sectoral Asset Management Portfolio holdings

AUM $121M
1-Year Est. Return 73.47%
This Fund
S&P 500
This Quarter Est. Return
+41.87%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$162M
AUM Growth
+$10.6M
Cap. Flow
-$25.2M
Cap. Flow %
-15.53%
Top 10 Hldgs %
35.02%
Holding
98
New
4
Increased
29
Reduced
28
Closed
16

Top Buys

Rank Stock Value
1
SI
Shoulder Innovations Inc
SI
+$6.01M
2
GPCR icon
Structure Therapeutics
GPCR
+$3.4M
3
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$3.06M
4
ANAB icon
AnaptysBio
ANAB
+$2.54M
5
TECX
Tectonic Therapeutic
TECX
+$1.94M

Top Sells

Rank Stock Value
1
LENZ
LENZ Therapeutics
LENZ
+$28.6M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$7.54M
3
RAPP
Rapport Therapeutics
RAPP
+$2.43M
4
REPL icon
Replimune Group
REPL
+$2.15M
5
PVLA
Palvella Therapeutics
PVLA
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 97.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JAZZ icon
76
Jazz Pharmaceuticals
JAZZ
$15.8B
$296K 0.18%
2,244
-30
-1% -$3.6K
ILMN icon
77
Illumina
ILMN
$30B
$259K 0.16%
2,727
-55
-2% -$5.46K
INCY icon
78
Incyte
INCY
$24B
$257K 0.16%
3,030
-3,030
-50% -$240K
PCVX icon
79
Vaxcyte
PCVX
$7.73B
$151K 0.09%
4,205
– –
MRNA icon
80
Moderna
MRNA
$21.9B
$145K 0.09%
5,600
– –
AXSM icon
81
Axsome Therapeutics
AXSM
$10.9B
$124K 0.08%
1,020
– –
MLTX icon
82
MoonLake Immunotherapeutics
MLTX
$1.48B
$6.86K ﹤0.01%
956
-14,152
-94% -$738K
CNC icon
83
Centene
CNC
$31.5B
– –
-12,500
Closed -$679K
CRSP icon
84
CRISPR Therapeutics
CRSP
$4.88B
– –
-2,540
Closed -$124K
CVRX icon
85
CVRx
CVRX
$146M
– –
-73,500
Closed -$432K
GMED icon
86
Globus Medical
GMED
$11.1B
– –
-13,500
Closed -$797K
IOBT
87
DELISTED
IO Biotech
IOBT
– –
-117,691
Closed -$164K
LEGN icon
88
Legend Biotech
LEGN
$3.68B
– –
-19,627
Closed -$697K
MEDP icon
89
Medpace
MEDP
$16B
– –
-531
Closed -$167K
REPL icon
90
Replimune Group
REPL
$1B
– –
-231,650
Closed -$2.15M
RVMD icon
91
Revolution Medicines
RVMD
$38.8B
– –
-6,240
Closed -$230K
RXRX icon
92
Recursion Pharmaceuticals
RXRX
$1.69B
– –
-11,500
Closed -$58.2K
SRRK icon
93
Scholar Rock
SRRK
$5.49B
– –
-10,380
Closed -$368K
TRML
94
DELISTED
Tourmaline Bio
TRML
– –
-116,510
Closed -$1.86M
VTRS icon
95
Viatris
VTRS
$20.5B
– –
-19,800
Closed -$177K
LENZ
96
LENZ Therapeutics
LENZ
$157M
– –
-977,245
Closed -$28.6M
KMTS
97
Kestra Medical Technologies
KMTS
$1.41B
– –
-35,000
Closed -$580K
CAI
98
Caris Life Sciences
CAI
$4.61B
– –
-8,350
Closed -$223K
1 2 3
4

Similar funds

RIP
Reliant Investment Partners Pinehurst, North Carolina $121M AUM 34.77% 1-Year Est. Return
LFWA
LiftPoint Family Wealth Advisors Far Hills, New Jersey $121M AUM
CF
Conquis Financial Milbrae, California $121M AUM 16.22% 1-Year Est. Return
WIM
Wiregrass Investment Management Thomasville, Georgia $121M AUM
MW
Merited Wealth North Bay Village, Florida $121M AUM
AFC
Avise Financial Cooperative Los Angeles, California $121M AUM
TGM
Tenzing Global Management San Francisco, California $121M AUM 85.62% 1-Year Est. Return
BIS
BG Investment Services Hagatna, Guam $120M AUM 17.44% 1-Year Est. Return

Sectoral Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Sectoral Asset Management held 98 positions worth $162M, up 7% from $151M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Sectoral Asset Management withdrew a net $25.2M in Q3 2025, closing 16 positions and reducing 28 holdings. Its most notable exit was LENZ Therapeutics, an estimated $28.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

Against the trend, Sectoral Asset Management opened a new position in Shoulder Innovations Inc worth $5.4M.

  • Sectoral Asset Management's largest Q3 2025 buy was Shoulder Innovations Inc: 430,282 shares worth $5.4M.
  • Sectoral Asset Management added most to Structure Therapeutics in Q3 2025, an estimated $3.4M increase.
  • Sectoral Asset Management's biggest Q3 2025 reduction was Mineralys Therapeutics, cutting an estimated $7.54M.
  • Sectoral Asset Management fully exited LENZ Therapeutics in Q3 2025, selling an estimated $28.6M.
  • Sectoral Asset Management's ten largest holdings make up 35% of its $162M portfolio in Q3 2025.
  • Sectoral Asset Management opened 4 new positions and closed 16 in Q3 2025.
  • Sectoral Asset Management's portfolio value rose 7% quarter-over-quarter to $162M.

Based on Sectoral Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.